Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells

Area of Science:

• Oncology
• Immunotherapy
• Cancer Biology

Background:

• Cancer stem cells (CSCs) are a subpopulation of tumor cells responsible for cancer initiation, maintenance, and recurrence.
• CSCs possess self-renewal and differentiation capabilities, contributing to therapeutic resistance against conventional chemo- and radiotherapy.

Purpose of the Study:

• To review common cancer stem cell populations and their markers.
• To explore the potential of chimeric antigen receptor (CAR) T-cell therapy in targeting cancer stem cells, particularly in solid tumors.

Main Methods:

• Literature review of cancer stem cell biology and immunotherapy.
• Analysis of CAR T-cell engineering, signaling, and application in targeting CSCs.
• Examination of challenges and barriers in applying CAR T-cell therapy to solid cancers.

Main Results:

• Identified key CSC markers including CD133, CD90, EpCAM, CD44, ALDH, and EGFRvIII.
• Discussed the interaction between CSCs and the immune system.
• Highlighted the potential and limitations of CAR T-cells in targeting CSCs for cancer treatment.

Conclusions:

• Targeted elimination of CSCs is crucial for effective cancer treatment and preventing recurrence.
• CAR T-cell therapy offers a promising avenue for targeting CSCs, though significant barriers remain for solid tumor applications.